Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

Paul Toren to Humans

This is a "connection" page, showing publications Paul Toren has written about Humans.

 
Connection Strength
  
 
 
0.152
  
  1. Friesen CS, Shakhnovich V, Toren P, Retke B, Schurman J, Colombo J, Deacy A, Friesen CA, Abdel-Rahman S. A Pilot Study of Ketotifen in Patients Aged 8-17 Years with Functional Dyspepsia Associated with Mucosal Eosinophilia. Paediatr Drugs. 2024 Jul; 26(4):451-457.
    View in: PubMed
    Score: 0.024
  2. Kyler KE, Gaedigk A, Abdel-Rahman S, Staggs VS, Pearce RE, Toren P, Leeder JS, Shakhnovich V. Influence of novel CYP2C-haplotype on proton pump inhibitor pharmacokinetics in children. Clin Transl Sci. 2024 04; 17(4):e13782.
    View in: PubMed
    Score: 0.024
  3. Tessman RT, Nolte W, Toren P, Gibson K, Vu L, Goldman J. Simultaneous quantification of trimethoprim metabolites in pediatric plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 May 15; 1198:123232.
    View in: PubMed
    Score: 0.021
  4. Chapron BD, Dinh JC, Toren PC, Gaedigk A, Leeder JS. The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metab Dispos. 2020 11; 48(11):1113-1120.
    View in: PubMed
    Score: 0.018
  5. Altman RA, Sharma KK, Rajewski LG, Toren PC, Baltezor MJ, Pal M, Karad SN. Tyr1-?[( Z)CF-CH]-Gly2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin. ACS Chem Neurosci. 2018 07 18; 9(7):1735-1742.
    View in: PubMed
    Score: 0.016
  6. Barbara JE, Kazmi F, Muranjan S, Toren PC, Parkinson A. High-resolution mass spectrometry elucidates metabonate (false metabolite) formation from alkylamine drugs during in vitro metabolite profiling. Drug Metab Dispos. 2012 Oct; 40(10):1966-75.
    View in: PubMed
    Score: 0.010
  7. Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011 Nov; 39(11):2020-33.
    View in: PubMed
    Score: 0.010
  8. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, Ogilvie BW. An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos. 2011 Aug; 39(8):1370-87.
    View in: PubMed
    Score: 0.010
  9. Toren P, Smith D, Chance R, Hoffman J. Determination of interchain crosslinkages in insulin B-chain dimers by fast atom bombardment mass spectrometry. Anal Biochem. 1988 Mar; 169(2):287-99.
    View in: PubMed
    Score: 0.008
  10. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos. 2006 Jan; 34(1):191-7.
    View in: PubMed
    Score: 0.007
  11. Reith K, Keung A, Toren PC, Cheng L, Eller MG, Weir SJ. Disposition and metabolism of 14C-rifapentine in healthy volunteers. Drug Metab Dispos. 1998 Aug; 26(8):732-8.
    View in: PubMed
    Score: 0.004
  12. Hortin G, Fok KF, Toren PC, Strauss AW. Sulfation of a tyrosine residue in the plasmin-binding domain of alpha 2-antiplasmin. J Biol Chem. 1987 Mar 05; 262(7):3082-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.